Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib with ADT for High-Risk Prostate Cancer
NCT04298983Phase 2Terminated
- Sponsor
- University of Alabama at Birmingham
- Start
- Feb 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abemaciclib in prostate cancer (PCa), sponsored by University of Alabama at Birmingham. Primary endpoint: Clinical Response Rates at 24 months. Started Feb 2021; status: terminated.
02
Drugs
abemaciclib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04298983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04298983.